APA (7th ed.) Citation

F, B., X, P., J, R., C, B., K, R., S, N., . . . B, G. (2021). Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(32), 3546. https://doi.org/10.1200/JCO.21.01152

Chicago Style (17th ed.) Citation

F, Bautista, et al. "Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 39, no. 32 (2021): 3546. https://doi.org/10.1200/JCO.21.01152.

MLA (9th ed.) Citation

F, Bautista, et al. "Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 39, no. 32, 2021, p. 3546, https://doi.org/10.1200/JCO.21.01152.